As we push ever closer to FDA approval for MDMA and psilocybin, and ketamine continues to grow in mental and physical health uses, one of the biggest hurdles in keeping the psychedelic medicine movement going is how to build safeguards that protect patients, practitioners, and other entities involved.
With traditional medicine, we have licensing and certification boards that not only dictate how practitioners can conduct themselves, but also which provide a means of action when a clinician doesn’t comport with the regulations that have been set.
Prior to now, such organizations did not exist for psychedelic medicine practitioners. However, we’re thrilled to announce that there is now a new organization that was formed to address these very concerns.
The American Psychedelic Practitioners Association (APPA) has taken on the task of setting standards for practitioners across the different psychedelic medicines and have set up a process for licensing in those areas as well.
To help educate us on all of the above, we gathered members from APPA to help us all get up to speed regarding:
- Who is behind this organization and how they were formed
- What the organization's missions are
- Who can join
- How one becomes board-certified or licensed
- How these safeguards will help foster the integration of psychedelic medicines into our current medical model
As always, there was ample time for audience Q & A, so be sure to watch till the end!


